{"nctId":"NCT04991311","briefTitle":"The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome","startDateStruct":{"date":"2021-08-10","type":"ACTUAL"},"conditions":["Short Bowel Syndrome"],"count":12,"armGroups":[{"label":"once-weekly glepaglutide","type":"EXPERIMENTAL","interventionNames":["Drug: Glepaglutide"]}],"interventions":[{"name":"Glepaglutide","otherNames":["ZP1848"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial\n* Age greater than or equal to 18 years and less than or equal to 90 years at screening\n* Stable condition of SBS either with intestinal failure (SBS-IF) or intestinal insufficiency. For patients with SBS-IF, a stable condition is defined as less than 25 percent change in parenteral support (PS) volume or energy content for 4 weeks prior to screening.\n* Stable body weight (less than 5 percent change in weight in the 3 months prior to screening)\n* Wet weight of fecal excretion greater than or equal to 1500 grams per day demonstrated during a hospital stay prior to screening\n\nExclusion Criteria:\n\n* More than 2 SBS-related or PS-related hospitalizations (e.g., catheter-related bacteremia/sepsis, bowel obstruction, severe water-electrolytes disturbances, etc.) within 6 months prior to screening\n* Poorly controlled inflammatory bowel disease (IBD) that is moderately or severely active or fistula interfering with measurements or examinations required in the trial\n* Current bowel obstruction\n* Known radiation enteritis or significant villous atrophy, e.g., due to active celiac disease\n* Cardiac disease defined as: decompensated heart failure (New York Heart Association \\[NYHA\\] Class III-IV), unstable angina pectoris, and/or myocardial infarction within the last 6 months prior to screening\n* Any history of colon cancer. History of any other cancers (except margin-free resected cutaneous basal or squamous cell carcinoma or adequately treated in situ cervical cancer) unless disease-free state for at least 5 years\n* Use of glucagon-like peptide-1 (GLP-1), GLP-2, human growth hormone (HGH), somatostatin, or analogs thereof, within 3 months prior to screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Absorption of Wet Weight/Fluids","description":"Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"841.6","spread":"1839.10"},{"groupId":"OG001","value":"1240.0","spread":"1529.74"}]}]}]},{"type":"SECONDARY","title":"Change in Absorption of Energy","description":"Oral intake minus fecal excretion: measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed. Energy absorption was measured by bomb calorimetry.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1037.7","spread":"1182.18"}]}]}]},{"type":"SECONDARY","title":"Change in Absorption of Carbohydrates","description":"Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.8","spread":"48.31"}]}]}]},{"type":"SECONDARY","title":"Change in Absorption of Lipids","description":"Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":"26.56"}]}]}]},{"type":"SECONDARY","title":"Change in Absorption of Proteins","description":"Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.65"}]}]}]},{"type":"SECONDARY","title":"Change in Absorption of Sodium","description":"Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","spread":"83.64"}]}]}]},{"type":"SECONDARY","title":"Change in Absorption of Potassium","description":"Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"26.44"}]}]}]},{"type":"SECONDARY","title":"Change in Absorption of Calcium","description":"Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"6.42"}]}]}]},{"type":"SECONDARY","title":"Change in Absorption of Magnesium","description":"Measured by 48-hour metabolic balance studies. The metabolic balance study measured the total intake and output of energy, macronutrients (lipids, carbohydrates, proteins) and micronutrients. The oral diet (food and fluids) was assessed by duplicate meals and liquids. During the metabolic balance study, the patients collected duplicate portions of all fluids and liquids covering 24-hour periods. Likewise, all output (ostomy output, diarrhea and urine production) was collected, quantified and analyzed.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"5.06"}]}]}]},{"type":"SECONDARY","title":"Change in Weekly Parenteral Support (PS) Volume","description":"Only for participants with Short Bowel Syndrome with Intestinal Failure (SBS-IF). PS use was recorded in patient diaries throughout the trial, including type and volume used.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4688.1","spread":"3150.67"}]}]}]},{"type":"SECONDARY","title":"Change in Weekly PS Volume","description":"Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5312.6","spread":"5463.54"}]}]}]},{"type":"SECONDARY","title":"Change in Weekly PS Carbohydrates","description":"Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3547.1","spread":"6375.32"}]}]}]},{"type":"SECONDARY","title":"Change in Weekly PS Carbohydrates","description":"Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4914.8","spread":"2452.10"}]}]}]},{"type":"SECONDARY","title":"Change in Weekly PS Lipids","description":"Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-260.3","spread":"1361.60"}]}]}]},{"type":"SECONDARY","title":"Change in Weekly PS Lipids","description":"Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.2","spread":"1869.08"}]}]}]},{"type":"SECONDARY","title":"Change in Weekly PS Proteins","description":"Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-879.3","spread":"1939.60"}]}]}]},{"type":"SECONDARY","title":"Change in Weekly PS Proteins","description":"Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1057.7","spread":"983.93"}]}]}]},{"type":"SECONDARY","title":"Change in Weekly PS Sodium","description":"Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-473.7","spread":"440.09"}]}]}]},{"type":"SECONDARY","title":"Change in Weekly PS Sodium","description":"Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-475.7","spread":"506.37"}]}]}]},{"type":"SECONDARY","title":"Change in Weekly PS Potassium","description":"Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.6","spread":"73.88"}]}]}]},{"type":"SECONDARY","title":"Change in Weekly PS Potassium","description":"Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-58.9","spread":"51.64"}]}]}]},{"type":"SECONDARY","title":"Change in Weekly PS Magnesium","description":"Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"9.02"}]}]}]},{"type":"SECONDARY","title":"Change in Weekly PS Magnesium","description":"Only for participants with SBS-IF. PS use was recorded in patient diaries throughout the trial, including type and volume used.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.8","spread":"14.84"}]}]}]},{"type":"SECONDARY","title":"Anti-glepaglutide Antibodies","description":"Monitored throughout the trial at baseline (Week 0) and weeks 4, 12, 24, 52 and 56","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Reactivity to ZP1848","description":"Monitored throughout the trial at baseline (Week 0) and weeks 4, 12, 24, 52 and 56. Anti-drug antibodies (ADA) positive samples were analyzed for reactivity to ZP1848.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Cross-reactivity to Glucagon-like Peptide-2 (GLP-2)","description":"Monitored throughout the trial at baseline (Week 0) and weeks 4, 12, 24, 52 and 56. ADA positive samples were analyzed for cross-reactivity to glucagon-like peptide-2 (GLP-2).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Glepaglutide Neutralizing Antibodies","description":"Monitored throughout the trial at baseline (Week 0) and weeks 4, 12, 24, 52 and 56","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":10},"commonTop":["Gastrointestinal stoma complication","Injection site pain","Injection site reaction","Oedema peripheral","Weight decreased"]}}}